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medical records including disease characteristics, treatment regimens, medications 
used and treatment outcomes. The study was conducted from the perspective of a 
Macao public hospital. The European Organization for Research and Treatment of 
Cancer quality-of-life questionnaire (EORTC QLQ-C30) (version 3.0, Chinese-Hong 
Kong) was used for the HRQoL assessment. RESULTS: The standard-dose melphalan-
based and vincristine-doxorubicin-dexamethasone-based regimens (VAD) were the 
most common treatment regimens. There were 24 and 10 patients in the melphalan-
based and VAD-based group respectively. Six patients were not studied due to incom-
plete data. Patients in the melphalan-based group were at a more advanced age (70.4 
± 7.4 years; p < 0.001). The melphalan-based group showed a lower overall treatment 
cost (MOP 29,231 versus MOP 44,831; p = 0.521, 1 USD = 8 MOP), especially on 
inpatient medication cost (MOP 5,809 versus MOP 13,908; p = 0.096). The VAD-
based group showed better clinical outcomes than the melphalan-based group in terms 
of overall survival, progression-free survival and survival probability with time. The 
incremental cost-effectiveness ratio of VAD-based regimens compared with melpha-
lan-based regimens was MOP 6,695 per life-year-gained. CONCLUSIONS: The 
results of this study suggest that the VAD-based regimens are very cost-effective 
according to the WHO recommended thresholds for cost-effectiveness in patients with 
MM in Macao.
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OPEN VERSUS LAPAROSCOPIC PROCEDURES FOR COLECTOMY 
SURGERY FOR PATIENTS WITH COLON RECTAL CANCER:  
A COST EFFECTIVENESS ANALYSIS, UNDER THE BRAZILIAN  
PRIVATE PAYER PERSPECTIVE
Nasciben V, Saggia MG
Johnson & Johnson, Sao Paulo-SP, Brazil
OBJECTIVES: To compare costs and outcomes of surgery techniques [open (OP) 
versus laparoscopic (LAP)] for colon rectal surgery in order to assess the impact on 
costs and clinical outcomes under the private payer perspective in Brazil. METHODS: 
A decision tree and a Markov model were developed according to the Brazilian 
guidelines for Health Technology Assessment (Vianna, 2007). Outcomes rates and 
probabilities for infection, mortality, conversion, survival, recurrence, sepsis and 
hernia were obtained from clinical literature (Gunnarsson 2008, King 2006, Bonjer 
2009, Murray 2006, Brazilian consensus for Sepsis 2003). A panel of specialists was 
conducted to validate the model and capture the local practice. Only direct medical 
costs were considered (Sources: SIMPRO, 2009; CBHPM 5th edition). A lifetime 
perspective was taken and a discount rate of 5% was applied (Vianna, 2007). A 
probabilistic sensitivity analysis was performed to assess the robustness of the results. 
RESULTS: Lengh of staying (LOS) was 9 days for OP versus 6 days for LAP resulting 
in a reduction of hospital costs and medical staff fees (R$5687 OP versus R$4445 
LAP). LAP also reduced the complication costs in 70% (-R$ 981 per procedure). Total 
costs were 8.52% higher for LAP than OP (R$22,085 vs. R$ 20,350), because of 
LAP’s devices costs (R$17,228 vs. R$13,270). In terms of outcomes, due mainly to 
the reduction of infection rate (OP 4.09% vs. 2.11% LAP) and the reduction of sepsis 
cases in 48.41% LAP showed an improvement on overall survival (1.31 years without 
discount and 0.36 years discounted). The sensitivity analysis showed that over 65% 
of the 5000 simulation were cost-effective. 1 USD = R$ 1.78 CONCLUSIONS: Find-
ings suggest LAP as a safer and cost-effective choice for colon cancer surgeries when 
compared with OP.
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COST-UTILITY OF KRAS MUTATION TESTING PRIOR TO  
TREATMENT OF METASTATIC COLORECTAL CANCER  
WITH CETUXIMAB MONOTHERAPY
Carlson JJ
University of Washington, Seattle, WA, USA
OBJECTIVES: To examine the cost-utility of using KRAS mutation testing prior to 
initiating cetuximab monotherapy for patients with metastatic colorectal cancer 
(mCRC) from a US payer perspective. METHODS: A decision analytic model was 
developed to evaluate the clinical and economic impact of three strategies for treating 
mCRC, 1) cetuximab monotherapy; 2) Best supportive care (BSC); and 3) KRAS 
mutation testing with cetuximab for KRAS wild type patients and BSC for patients 
harboring a KRAS mutation. Model parameters were derived from the CO.17 trial, 
published literature, and government sources. The model included trial-based survival 
estimates and adverse event rates as well as costs related to drug treatment and 
administration, KRAS testing, adverse events, and post-progression care. The model 
results were examined using one-way and probabilistic sensitivity analyses. RESULTS: 
Total QALYs for the cetuximab, BSC, and KRAS testing strategies were 0.47, 0.36, 
and 0.47, respectively. Total costs were $44,301; $6,364; and $34,263, respectively. 
Relative to BSC, cetuximab for all and KRAS testing strategies had incremental cost-
effectiveness ratios of $357,224 and $264,644 per QALY, respectively. Relative to 
cetuximab for all, the KRAS testing strategy saved $10,037 with a negligible decrease 
in QALYs. One-way sensitivity analyses found the results to be most sensitive to the 
survival estimates, cost of cetuximab, and the pre progression utility score. In the 
probabilistic sensitivity analysis, BSC had the highest probability of being cost-effec-
tive until a willingness-to-pay of $275,000, after which KRAS testing had the highest 
probability. CONCLUSIONS: These results suggest that the use of KRAS testing to 
select patients for cetuximab treatment in mCRC can reduce costs with a negligible 
impact on QALYs as compared to using cetuximab for all patients. However, the 
cost-effectiveness of KRAS testing vs. best supportive care remains well above com-
monly used cost-effectiveness thresholds.
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SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR 
CARCINOMA (AHCC): THE PRIVATE HEALTH CARE SYSTEM 
PERSPECTIVE IN BRAZIL
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OBJECTIVES: Sorafenib improves survival in AHCC (Llovet, NEJM 2008), and has 
been considered cost-effective in Canada (Muszbek, Curr Med Res Opin 2008), when 
compared with BSC. In clinical practice, however, patients with AHCC with no access 
to sorafenib are often treated with other systemic agents, none of which are able to 
improve the outcome. The objective of this study was to evaluate the cost-effectiveness 
of sorafenib+BSC vs BSC alone in Brazil, from the perspective of the private health-
care system. METHODS: A Markov model was developed to project the lifetime 
survival and costs for both interventions using data from the TTP and OS Kaplan-
Meier curves from SHARP trial in a lognormal distribution and from an ad hoc panel 
with Brazilian medical oncologists, hepatologists, and liver surgeons. Treatment effec-
tiveness was measured in life-years gained (LYG). Resource utilization included drug, 
administration, physician visits, monitoring, and adverse events. Costs (in R$, with 
R$ 1.00 ∼ US$ 0.58) and survival beneﬁts were discounted annually at 5%. Univariate 
and probabilistic sensitivity analyses were conducted. RESULTS: Lifetime per-patient 
costs in R$ (US$) were 103,210 (58,977) and 10,435 (5,963) for sorafenib+BSC and 
BSC alone, respectively. Sorafenib drug cost accounted for nearly 80% of treatment 
costs. The incremental survival beneﬁt with sorafenib+BSC was 0.49 life-years. The 
incremental cost-effectiveness ratio of sorafenib+BSC vs BSC alone was R$ 189,402 
(US$ 108,230) per LYG. CONCLUSIONS: The addition of sorafenib to BSC is the 
only intervention that has been found to improve survival in AHCC and the cost-
effectiveness results reﬂects the increased cost of an active treatment when compared 
with a low cost and ineffective alternative.
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COST-EFFECTIVENESS OF LENOGRASTYM ON NEUTROPENIA 
DURATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR LEUKEMIA
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OBJECTIVES: Number of studies shown beneﬁcial effect of granulocyte colony-
stimulating factors (G-CSF) on neutropenia duration in children receiving chemo-
therapy for leukemia. The aim of present analysis was to assess cost-effectiveness of 
lenograstim in comparison with ﬁlgrastim in Polish settings (threshold is about 
100,095 PLN). METHODS: Analysis covered time horizon of one chemotherapy 
cycle. A public payer perspective was adopted for cost analysis. The costs included 
were based on Polish NHF reference costs list. Data on time to ANC recovery, number 
of days with fever, length of hospital stay and antibiotics use were obtained from 
randomized controlled trials (RCTs) identiﬁed in the conducted systematic review. 
These included trials on prophylactic G-CSF use as well as trials in which only patients 
with neutropenia were included. Equations describing costs and QALY according to 
neutropenia and fever length, hospital stay and antibiotic use were established. 
RESULTS: Estimated QALY difference between lenograstim and ﬁlgrastim is 0.0011 
(CI95%[0.0006; 0.0016]). Total costs difference between lenograstim and ﬁlgrastim is 
−533 PLN (CI95%[−1,052; −28]) Probability of lenograstim being cost-effective over 
ﬁlgrastim is 99.16%. Taking into account only trials where G-CSFs were used in 
neutropenia prophylaxis estimated QALY difference between lenograstim and ﬁlgras-
tim is 0.0014 (CI95%[0.0008; 0.0020]). Total costs difference between lenograstim and 
ﬁlgrastim is −699 PLN (CI95%[−1,376; −32]). Probability of lenograstim being cost-
effective over ﬁlgrastim is 98.98%. CONCLUSIONS: Lenograstim is dominant over 
ﬁlgrastim. Acknowledgements: This analysis was supported by Sanoﬁ-Aventis.
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THE GRANULOCYTE-COLONY STIMULATING FACTOR (GCSF) IN 
PREPARATION FOR AN AUTOLOGOUS HEMATOPOIETIC STEM CELL 
TRANSPLANTATION ON PATIENTS WITH NON HODGKIN’S 
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OBJECTIVES: To estimate the average and incremental cost effectiveness ratios for 
the plerixafor+GCSF treatment, compared to just a GCSF, in preparation for an 
autologous hematopoietic stem cell transplantation on patients with Non Hodgkin’s 
Lymphoma from the institutional perspective in the Mexican context. METHODS: 
Cost-effectiveness analysis by using a decision tree, to compare the costs and results 
of using a Granulocyte-Colony Stimulating Factor vs. GCSF and plerifaxor, from the 
institutional perspective. A 2 year temporal horizon was considered. The effectiveness 
measurement used, took into consideration the percentage of patients that survive the 
transplantation or graft and was obtained from published medicine based clinical 
studies. Only direct medical costs taken from the mexican health system were evalu-
ated. A 5% discount rate was taken into account and a univariated sensitivity analysis 
using relevant variables was summarized in seven scenarios. RESULTS: The GCSF + 
plerixafor treatment demonstrated the least average cost per transplanted patient with 
US$33,291 vs. US$39,768 for treatment with GCSF (1 USD = 13.5MXN) . According 
to the model, effectiveness in relation to the survival of transplanted patients after 2 
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years, was 95.1% in the case of GCSF+plerixafor therapy compared to 42.61% for 
GCSF. Additionally, the average reported cost for GCSF+plerixafor treatment in suc-
cessful cases was $35,020, and in the case of a GCSF treatment the cost totaled 
US$93,325, which represents a 62% saving for an actual year of therapy. Therefore, 
the GCSF+Plerixafor treatment results in a more effective, less costly, and ﬁnally the 
most viable alternative. CONCLUSIONS: The GCSF+Plerixafor treatment is a cost 
effective alternative, from a Mexican institutional perspective for Non Hodgkin’s 
Lymphoma patients in preparation for an autologous hematopoietic stem cell 
transplantation.
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COST EFFECTIVENESS ANALYSIS OF BREAST CANCER RISK 
REDUCTION THERAPY: COMPARING TAMOXIFEN AND RALOXIFENE
Poon JL, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To illustrate the relative value of raloxifene compared to tamoxifen, 
in the chemoprevention of invasive breast cancer in postmenopausal women in the 
United States. METHODS: Using outcomes data from the NSABP P-2 trial, a back-
ward induction model was performed from the societal perspective, comparing tamox-
ifen and raloxifene in postmenopausal women aged 35 to 80 years, with base case 
5-year breast cancer risk of 4.03%. Secondary outcomes considered were thrombo-
embolic events, cataracts, uterine hyperplasia and hysterectomy. Quality adjusted life 
years (QALY) gained from using raloxifene versus tamoxifen was estimated by con-
sidering the quality adjusted life expectancies for all model outcomes for each drug. 
Costs were in 2009 US dollars and costs and outcomes were discounted at an annual 
rate of 3%. An incremental cost effectiveness ratio (ICER) decision threshold of 
US$150000/QALY gained was used to determine age-cohort speciﬁc cost-effective-
ness. One-way sensitivity analyses were performed on outcome parameters and the 
discount rate, and threshold analyses were performed on parameters the model was 
sensitive to. RESULTS: Raloxifene was found to be cost effective relative to tamoxifen 
for all age-cohorts in the model, with ICERs between US$25,631 and US$30,133/
QALY gained at age 60 and 35 respectively. The model was most sensitive to raloxi-
fene cost, the ICER varying by +/-26.5% when the cost varied by +/-25%. The model 
was also sensitive to the probability of developing cataracts and requiring a hysterec-
tomy when on tamoxifen therapy. For raloxifene to not be cost-effective raloxifene 
costs would have to increase 5.7 times or the probability of developing cataracts or 
requiring hysterectomy when on tamoxifen therapy would have to reduce to zero and 
by 21 times respectively. CONCLUSIONS: Raloxifene was found to be cost effective 
compared to tamoxifen in the target population due to its more favourable adverse 
effect proﬁle, despite both drugs having similar efﬁcacy in the chemoprevention of 
breast cancer.
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ECONOMIC EVALUATION OF SUNITINIB VS. INTERFERON-A AND 
BEVACIZUMAB + INTERFERON-A IN THE TREATMENT OF METASTATIC 
RENAL CELL CARCINOMA (CCRM) – BRAZILIAN PRIVATE HEALTH 
SYSTEM PERSPECTIVE
Teich V1, Hashizume CM2, Marinho T1, Charbonneau C3, Naves A2
1Medinsight, Rio de Janeiro, RJ, Brazil, 2Pﬁzer Brazil, Sao Paulo, SP, Brazil, 3Pﬁzer, Inc., New 
York, NY, USA
OBJECTIVES: Elaborate an economic evaluation based in a cost-effectiveness model 
to compare sunitinib versus interferon-α (IFNα) and bevacizumab + IFNα as ﬁrst line 
therapy for metastatic renal clear cell carcinoma, in Brazilian Private Health System 
perspective. METHODS: A Markov model, with 6 weeks cycles and a 2-year time 
horizon was developed in Microsoft Excel to evaluate the cost-effectiveness of suni-
tinib vs. IFNα and bevacizumab + IFNα, considering resources from the Brazilian 
Private Health Care. The model considered that the patients received active treatment 
until drug fail. After progression conﬁrmation, patients were treated with a second 
line of active treatment or best supportive care (progression monitoring and palliative 
treatment). Results were expressed as life-years (LY) gained, progression-free LY 
(PFLY) gained, treatment costs, and incremental cost-effectiveness ratios (ICER) 
RESULTS: In comparison with IFNα, sunitinib increases LY and PFLY by 0.08 and 
0.33 years respectively, with ICER of R$324,172 (US$190,689 Purchasing Power 
Parity 2009, 1US$ = 1,7R$). In comparison with bevacizumab + IFNα, sunitinib was 
dominant as both more effective (with 0.04 LY and 0.09 PFLY gained) and less costly, 
with a negative ICER of R$ 2,169,212 (US$ 1,549,437) over 2 years, meaning a cost 
saving of R$ 2,169,212 over the combination therapy. CONCLUSIONS: This model 
suggests that when taking the perspective of the Brazilian Private Health Care System 
, sunitinib achieved overall cost saving with improved survival when compared with 
bevacizumab + IFNα in a 2 years time horizon. In comparison to IFNα, sunitinib 
promoted better results on efﬁcacy parameters, with an incremental cost in the same 
time horizon.
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COST-EFFECTIVENESS ANALYSIS OF MULTIMODAL SCREENING FOR 
OVARIAN CANCER
Ding Y, Hay J
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OBJECTIVES: The main objective was to assess cost-effectiveness of multimodal 
screening for ovarian cancer (Annual screening with CA125 marker, followed by 
transvaginal ultrasound for those at increased risk according to CA125 level) from the 
US societal perspective. The secondary objective was to facilitate an economic compari-
son between two different screening strategies (multimodal screening and ultrasound 
screening), which have been proven to be effective in improving early detection of 
ovarian cancer. METHODS: A lifetime incremental cost-effectiveness model was con-
structed to calculate the increase of costs, and QALYs gained by the multimodal screen-
ing. In this ‘backward induction’ model, the expected costs and outcomes for each 
5-year time-interval are incorporated in subsequent 5-year time period calculations 
over the patient’s entire lifetime. The sensitivity and speciﬁcity of screening, and the 
stage distribution of detected ovarian cancer by the screening were obtained from the 
NCT00058032 clinical trial. The model used a 3% discount rate and reported results 
in 2009 US dollars. RESULTS: Over a lifetime, multimodal screening was estimated to 
cost an additional $820 with an expected gain of 0.0037 quality adjusted life years 
(QALY) or an incremental cost-effectiveness ratio (ICER) of $221,622/ QALY com-
pared to no screening for age 65–69 postmenopausal females. Compared with annual 
transvaginal ultrasound (TVU) screening, multimodal screening improves cost-effec-
tiveness by avoiding unnecessary TVU and surgery, which are risky to the patient and 
costly to the health care system. Cancer incidence rates and time required for screening 
exhibited substantial impact on the model from sensitivity analyses. CONCLUSIONS: 
Multimodal screening is not clearly cost-effective, compared to commonly accepted 
willingness-to-pay thresholds in oncology ($120,000–$150,000/QALY). If high risk 
women were selected for multimodal screening or if the screening was administered as 
part of another medical ofﬁce visit in order to decrease the time required for screening 
test, the ICER could be lower than $120,000/QALY.
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COST-EFFECTIVENESS OF PROMOTORA LED HEALTH EDUCATION 
INTERVENTIONS TO INCREASE CERVICAL CANCER SCREENING 
AMONG LOW INCOME HISPANIC WOMEN
Lairson DR1, Chang YC2, Byrd TL3, Smith JL4, Wilson KM4
1University of Texas Houston School of Public Health, Houston, TX, USA, 2University of 
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OBJECTIVES: We conducted an economic evaluation with cost and outcome data 
from a randomized controlled trial of promotora led interventions to increase cervical 
cancer screening among three populations of low income Hispanic women. 
METHODS: Hispanic women of Mexican origin, age 21 to 65, with no previous 
cervical cancer, no hysterectomy, and no Pap test within the last 3 years from El Paso, 
Houston, TX and Yakima Valley, WA were randomly assigned to four intervention 
arms, control, video, ﬂip chart, and full (combination of video and ﬂip chart) interven-
tion. Micro costing, including recruitment cost, from both payer and client perspec-
tives were used to estimate intervention costs. Effectiveness measures were the 
prevalence of a self-reported pap test within 6 months after the intervention, analyzed 
under the condition of intention- to- treat. Incremental cost effectiveness ratios 
(ICERs) were the incremental cost per additional women screened. Uncertainty was 
examined with sensitivity analyses. RESULTS: The total cost per participant, was 
$216 for video, $219 for ﬂip chart, and $223 in the full intervention. The proportion 
of women reporting a Pap test was 0.261 in the control arm, 0.484 in the video arm, 
0.515 in the ﬂipchart arm and 0.568 in the full intervention arm. The ICERs were 
$968 comparing the control arm to the movie, $94 comparing the movie to ﬂip chart 
arm and $72 comparing ﬂip chart to the full intervention arm. CONCLUSIONS: The 
promotora led full interventions had important and statistically signiﬁcant effects on 
screening behavior and compare favorably with the other two strategies designed to 
promote cervical cancer screening in the study. The study provides economic informa-
tion for health educators in designing and budgeting promotora based cancer screening 
promotion programs for low income Hispanic women.
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COST-EFFECTIVENESS ANALYSIS OF EGFR MUTATION TESTING IN 
PATIENTS WITH ADVANCED NON SMALL-CELL LUNG CANCER 
(ANSCLC) TREATED WITH GEFITINIB OR CARBOPLATIN-PACLITAXEL
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OBJECTIVES: To assess the cost-effectiveness of an EGFR mutation testing strategy 
when considering 1st-line therapy of aNSCLC with geﬁtinib for mutation positive and 
carboplatin-paclitaxel (CP) for mutation negative disease. METHODS: A Discrete 
Event Simulation (DES) was designed to emulate two strategies for treating patients 
with aNSCLC. In the ﬁrst strategy, patients were tested for EGFR genetic mutation 
and given geﬁtinib if positive and CP if negative. In the second strategy patients were 
not tested for genetic mutation and all of them received CP treatment. Probabilities 
for adverse events and progression-free survival (PFS) were obtained from the IPASS 
clinical study (Mok et al 2009). The mutation rate used was 13% and a sensitivity 
analysis was run over this variable. A Markov model using micro simulation was also 
built to compare results of the DES model and assure internal validity. Both models 
were run 10 times with 1000 patients for each strategy. Cost-effectiveness ratios were 
obtained for the testing and not-testing strategies and particularly for positive tested 
patients treated with geﬁtinib. RESULTS: Mean PFS (generated by DES) of tested 
patients with mutation positive disease treated with geﬁtinib was 11.51 (95% CI, 
11.10–11.92) months. PFS of patients who where tested for EGFR mutation (positive 
and negative) was 7.57 (95% CI, 7.50–7.64) months. Patients in the second strategy 
(without testing) yielded 7.11(95% CI, 7.05–7.17) progression-free months. Incremen-
tal cost-effectiveness ratio (ICER) of the testing strategy (including test cost) over the 
not-testing strategy was $1379.49 (95% IC, $1102.10–$1656.88) per progression-free 
month. CONCLUSIONS: According to this analysis, testing aNSCLC patients for 
